Global multiple sclerosis drugs market is estimated to reach $29.46 billion by 2026; growing at a CAGR of 6.3% till 2026.
Table of Content 1. Market Introduction 1.1. Executive Summary 1.2. Market Definition 1.3. Market Scope 2. Research Methodology 2.1. Primary Research 2.2. Research Methodology 2.3. Assumptions & Exclusions 2.4. Secondary data sources 3. Multiple Sclerosis Drugs Market Overview 3.1. Report Segmentation & Scope 3.2. Key Market Trend 3.3. Drivers 3.3.1. Growing demand from expensive multiple sclerosis drugs 3.3.2. Increased research in the field of MS to develop innovative therapies 3.4. Restraints 3.4.1. High cost of MS drugs 3.4.2. Non-availability of drugs 3.5. Opportunities 3.5.1. Advancements in biomedical science 3.5.2. Mergers and acquisitions among top manufacturing companies 3.6. Porter’s Five Forces Analysis 3.6.1. Porter’s Five Forces Analysis 3.7. Market Share Analysis 4. Drug Class Overview 4.1. Introduction 4.1.1. Market Size & Forecast 4.2. Sphingosine 1 Phosphate Receptor Modulators 4.2.1. Market Size & Forecast 4.3. Mixed Polymers 4.3.1. Market Size & Forecast 4.4. Interferon β 4.4.1. Market Size & Forecast 4.5. Monoclonal Antibodies 4.5.1. Market Size & Forecast 4.6. Pyrimidine Synthesis Inhibitors 4.6.1. Market Size & Forecast 4.7. Others 4.7.1. Market Size & Forecast 5. Route of Administration Overview 5.1. Introduction 5.1.1. Market Size & Forecast 5.2. Oral 5.2.1. Market Size & Forecast 5.3. Injectable 5.3.1. Market Size & Forecast 6. Distribution Channels Overview 6.1. Introduction 6.1.1. Market Size & Forecast 6.2. Retail Pharmacies 6.2.1. Market Size & Forecast 6.3. E-Commerce 6.3.1. Market Size & Forecast 6.4. Hospital Pharmacies 6.4.1. Market Size & Forecast 7. Multiple Sclerosis Drugs Market Regional Overview 7.1. Introduction 7.1.1. Market Size & Forecast 7.2. North America Multiple Sclerosis Drugs Market 7.2.1. North America Market Size & Forecast, By Country 7.2.2. North America Market Size & Forecast, By Drug Class 7.2.3. North America Market Size & Forecast, By Route of Administration 7.2.4. North America Market Size & Forecast, By Distribution Channels 7.2.5. U.S. 7.2.5.1. Market Size and Forecast 7.2.6. Canada 7.2.6.1. Market Size and Forecast 7.2.7. Mexico 7.2.7.1. Market Size and Forecast 7.3. Europe Multiple Sclerosis Drugs Market 7.3.1. Europe Market Size & Forecast, By Country 7.3.2. Europe Market Size & Forecast, By Drug Class 7.3.3. Europe Market Size & Forecast, By Route of Administration 7.3.4. Europe Market Size & Forecast, By Distribution Channels 7.3.5. Germany 7.3.5.1. Market Size and Forecast 7.3.6. France 7.3.6.1. Market Size and Forecast 7.3.7. UK 7.3.7.1. Market Size and Forecast 7.3.8. Italy 7.3.8.1. Market Size and Forecast 7.3.9. Spain 7.3.9.1. Market Size and Forecast 7.3.10. Rest of Europe 7.3.10.1. Market Size and Forecast 7.4. Asia-Pacific Multiple Sclerosis Drugs Market 7.4.1. Asia-Pacific Market Size & Forecast, By Country 7.4.2. Asia-Pacific Market Size & Forecast, By Drug Class 7.4.3. Asia-Pacific Market Size & Forecast, By Route of Administration 7.4.4. Asia-Pacific Market Size & Forecast, By Distribution Channels 7.4.5. Japan 7.4.5.1. Market Size and Forecast 7.4.6. China 7.4.6.1. Market Size and Forecast 7.4.7. Australia 7.4.7.1. Market Size and Forecast 7.4.8. India 7.4.8.1. Market Size and Forecast 7.4.9. South Korea 7.4.9.1. Market Size and Forecast 7.4.10. Rest of Asia-Pacific 7.4.10.1. Market Size and Forecast 7.5. South America Multiple Sclerosis Drugs Market 7.5.1. South America Market Size & Forecast, By Country 7.5.2. South America Market Size & Forecast, By Drug Class 7.5.3. South America Market Size & Forecast, By Route of Administration 7.5.4. South America Market Size & Forecast, By Distribution Channels 7.5.5. Brazil 7.5.5.1. Market Size and Forecast 7.5.6. Argentina 7.5.6.1. Market Size and Forecast 7.5.7. Rest of South America 7.5.7.1. Market Size and Forecast 7.6. Middle East & Africa Multiple Sclerosis Drugs Market 7.6.1. Middle East & Africa Market Size & Forecast, By Country 7.6.2. Middle East & Africa Market Size & Forecast, By Drug Class 7.6.3. Middle East & Africa Market Size & Forecast, By Route of Administration 7.6.4. Middle East & Africa Market Size & Forecast, By Distribution Channels 7.6.5. GCC Countries 7.6.5.1. Market Size and Forecast 7.6.6. Egypt 7.6.6.1. Market Size and Forecast 7.6.7. South Africa 7.6.7.1. Market Size and Forecast 7.6.8. Rest of Middle East & Africa 7.6.8.1. Market Size and Forecast 8. Company Profile 8.1. Glaxosmithkline 8.1.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 8.1.2. Glaxosmithkline Product Category, Application, and Specification 8.1.3. Glaxosmithkline Financial Performance (2016-2018) 8.1.4. Main Business/Business Overview 8.2. Novartis AG 8.3. Gw Pharmaceuticals 8.4. Innate Immunotherapeutics 8.5. Genzyme 8.6. Genmab 8.7. Artielle Immunotherapeutics 8.8. Apitope 8.9. Five Prime Therapeutics 8.10. Daiichi Sankyo 8.11. Eli Lilly 8.12. Fast Forward Llc 8.13. Antisense Therapeutics 8.14. Cinnagen 8.15. Bayer AG